<Blinded Review: TIME_ANON_0885>
**Composite Score:** 3.6 / 10.0 (Rigor: 1.0/3.5 | Claims: 0.8/2.5 | Biology: 0.8/2.0 | Reproducibility: 1.0/2.0)
**Bias Category:** Technical/Assay
**Verdict:** Reject (Fundamental Flaws)
**Study Modality:** Hybrid Computational + Wet-Lab
**Technology Maturity:** Mature/Classical
**Epistemic Stage:** Clinical/Observational

OVERALL_SCORE: 3.6/10
VERDICT: FAILED
ESTIMATED_DECADE: 2020s

---

### 1. Executive Summary / SUMMARY
This molecular epidemiology study screens 200 post-mortem nasopharyngeal/oropharyngeal swabs collected within 6 hours of death from individuals with influenza-like illness (ILI) in Shiraz, Iran, over a single peak pre-COVID-19 influenza season. Real-time RT-PCR identified 30 influenza A-positive cases, of which 21 were confirmed as influenza A(H1N1)pdm09. Due to RNA quality and financial constraints, 11 of the 21 positive isolates were selected for conventional RT-PCR and Sanger sequencing of the hemagglutinin (HA) and neuraminidase (NA) genes, followed by Neighbor-Joining (NJ) phylogenetic analysis in MEGA 7 and amino acid substitution mapping against the A/California/07/[YEAR] and A/Brisbane/02/[YEAR] vaccine reference strains. While the GenBank accessions are deposited, a close audit of the manuscript text and tables uncovers numerous internal contradictions between the text and Tables 5/6, miscalculated mutation frequencies, contradictory nucleotide identity ranges between sections, and overstatements of standard clade-defining lineage markers as "uniquely identified" mutations.

### 2. Methodological & Statistical Audit / STRENGTHS & WEAKNESSES & METHODOLOGICAL AUDIT

#### STRENGTHS
- **Public deposition of primary HA and NA sequences:** All 11 HA sequences (`PX128436`–`PX128446`) and 11 NA sequences (`MZ540082`, `MZ540084`, `MZ853929`–`MZ853937`) are deposited in GenBank.
- **Post-mortem severe/fatal case sampling:** Sampling within 6 hours of death provides sequence data from fatal influenza cases in southern Iran.

#### WEAKNESSES & METHODOLOGICAL AUDIT
- **Severe internal contradictions between the text and Table 5 / Table 6:**
  1. **S185T vs. S185I and impossible percentages:** In the Results (line 105), the authors report `S185T (4/11)` (which is $36.4\%$). In Table 5 (lines 114–124), only **3** isolates (`HAVRC001`, `HVRC002`, `HVRC003`) have `T` at position 185, while the remaining **8** isolates (`HVRC004`–`HVRC011`) have `I` (`S185I`)! Then, in line 164, the authors state that *"all isolates exhibited characteristic mutations in the HA gene... namely S185T, S203T, K163Q, and D222G"*, and two sentences later (line 166) state that `S185T` is a *"less frequent S185T (3%) mutation in the Sb site"*! Note that $3/11 = 27.3\%$, not $3\%$ (the authors confused the count 3 with $3\%$), and 8/11 isolates actually carry `S185I`.
  2. **D222G frequency contradiction:** In the Abstract (line 11) and line 164, `D222G` is described as a characteristic mutation across the isolates; in Table 5, `D222G` is present in 3 of 11 isolates (`HVRC002`, `HVRC003`, `HVRC010`, i.e., $27.3\%$, alongside 1 `D222N` and 1 `D222V`), whereas line 166 reports `D222G` as `"a subset of isolates (3%)"`—again confusing the integer count of 3 isolates with "3%"!
  3. **S162N, K163Q, and S203T falsely claimed as differences from A/Brisbane/02/[YEAR]:** In line 168, the authors state: *"Compared with the A/Brisbane/02/[YEAR] vaccine strain, all isolates from our study exhibited key amino acid differences in the HA protein, including K163Q, S162N, and S203T (Table 5)."* Yet looking directly at Table 5 (line 113), `A/Brisbane/02/[YEAR]` **already has `N` at 162, `Q` at 163, and `T` at 203**—identical to the Shiraz isolates! Those substitutions distinguish clade 6B.1 (including A/Brisbane/02/[YEAR]) from the ancestral A/California/07/[YEAR] strain, not from A/Brisbane/02/[YEAR].
  4. **I216T claimed in "all strains":** The Abstract (line 11) states *"All strains isolated from deceased patients belonged to subclade 6B.1, with I216T and S162N mutations."* Yet in Table 5 (line 118), isolate `A/shiraz/HVRC005` has `.` (wild-type `I`) at position 216 (10/11, not 11/11).
  5. **H275Y frequency and mechanism misstated:** In the Abstract (line 11), `H275Y` is reported in *"5% of reported sequences"*, whereas 1 out of 11 sequenced NA genes is $9.1\%$ (1/11), or 1 out of 21 PCR-positive cases is $4.8\%$. Worse, line 170 states: *"The H275Y mutation reduces resistance to oseltamivir"*—the exact opposite of biological reality (H275Y *confers* resistance / *reduces susceptibility* to oseltamivir).
  6. **Q51K, F74S, D416N contradiction:** Line 170 states: *"Additionally, the Q51K (72.7%), F74S (72.7%), and D416N (81.8%) mutations... were uniformly noted across all strains"*. A mutation present in $72.7\%$ (8/11) or $81.8\%$ (9/11) of strains is by definition not "uniformly noted across all strains."
- **Contradictory nucleotide identity numbers between consecutive sections:**
  - In line 66 (Results: Demographic Data), nucleotide identity to `A/California/07/[YEAR]` is reported as **98.6% to 99.4%** for HA and **98.8% to 99.7%** for NA.
  - Just 80 lines later, in line 146 (Results: Sequence Comparisons), nucleotide identity of the exact same 11 strains to `A/California/07/[YEAR]` is reported as **97.4% to 99.3%** for HA and **97.7% to 99.6%** for NA!
- **Selection bias and lack of mild/surviving comparator group:** Only 11/21 positive deceased cases were sequenced, and no surviving/outpatient ILI controls from the same season were sequenced; thus, mutations cannot be statistically associated with fatal outcome vs. background seasonal circulation.
- **Outdated phylogenetic method:** Neighbor-Joining (NJ) without explicit nucleotide substitution model selection or Maximum Likelihood validation is suboptimal for viral molecular epidemiology.

### 3. Biological / Experimental Grounding & Claim Proportionality
- **Claim 1:** All 11 Shiraz isolates belong to influenza A(H1N1)pdm09 subclade 6B.1, sharing S162N, K163Q, and S203T relative to A/California/07/[YEAR]. `[Well Supported]` — Confirmed by Table 5 and GenBank sequences.
- **Claim 2:** S185T, S203T, K163Q, and D222G were "uniquely identified within our study" (line 159) and distinguish the Shiraz isolates from A/Brisbane/02/[YEAR] (line 168). `[Methodologically Flawed]` — Directly contradicted by Table 5 (where A/Brisbane/02 already carries S162N, K163Q, S185T, and S203T) and by global H1N1pdm09 clade 6B.1 surveillance.
- **Claim 3:** D222G and S185T were present in 3% of isolates, and H275Y in 5% of sequences. `[Methodologically Flawed]` — Confuses the count of 3/11 ($27.3\%$) with "3%" and 1/11 ($9.1\%$) with "5%".

### 4. Reproducibility & Data Completeness
- **Sequence Availability:** GenBank accession numbers for all 11 HA and 11 NA sequences are provided (Tables 3 and 4).
- **Primer Completeness:** Real-time detection primers are listed in Table 1 (though the probe sequence `Fam-CYACTGCAAGCCCAXACACACAAGCAGGCA-BHQ` contains an undefined base `X`), while the conventional RT-PCR amplification and Sanger sequencing primers for full-length HA and NA are omitted.
</Blinded Review: TIME_ANON_0885>
